Thyroid hormone affects the contractile and electrophysiological properties of the cardiac myocyte that result in part from changes in the expression of thyroid hormone-responsive cardiac genes, including those that regulate membrane ion currents. To determine the molecular mechanisms underlying this effect, expression of a voltagegated K ϩ channel, Kv1.5, was measured in response to thyroid hormone. Using quantitative RT-PCR methodology, the content of Kv1.5 messenger RNA (mRNA) in left ventricles of euthyroid rats was 4.25 Ϯ 0.6 ϫ 10 Ϫ20 mol/g total RNA and was decreased by 70% in the hypothyroid rat ventricle to 1.27 Ϯ 0.80 ϫ 10 Ϫ20 mol/g RNA (P Ͻ 0.01). Administration of T 3 to hypothyroid animals restored ventricular Kv1.5 mRNA to control levels within 1 h of treatment, making this the most rapid T 3 -responsive cardiac gene reported to date. The half-life of Kv1.5 mRNA was 1.9 h and 2.0 h in euthyroid and hypothyroid ventricles, respectively, and T 3 treatment of the rats did not alter its half-life. In atrial myocardium, expression of Kv1.5 mRNA (6.10 Ϯ 0.37 ϫ 10 Ϫ20 mol/g RNA) was unaltered by thyroid hormone status. The myocyte-specific and chamber-selective expression of Kv1.5 mRNA was confirmed in primary cultures of rat atrial and ventricular myocytes. (Endocrinology 140: 3170 -3176, 1999) T HYROID hormone exerts prominent and characteristic effects on the cardiovascular system (1). Hyperthyroidism is associated with sinus tachycardia and atrial fibrillation, whereas the hypothyroid patient may experience bradycardia with prolonged QT intervals and polymorphic ventricular tachycardia or "torsade de pointes" (2, 3). Thyroid hormones regulate the expression of specific cardiac genes (4, 5) and have also been shown to directly alter plasma membrane ion currents, including the outward K ϩ rectifying current (6), the inward rectifier K ϩ current, I K1 (7), and sodium currents (8, 9). These effects may in turn alter action potential duration and susceptibility to ventricular arrhythmias. Regulation of the Kv1.5 gene has been shown in response to cardiac growth and development (10), cAMP in cultured neonatal rat atrial myocytes (11), and glucocorticoids in ventricular myocytes (12). A recent study using adrenalectomized rats that were rendered hypothyroid suggested that induction of Kv1.5 gene transcription [as measured by messenger RNA (mRNA)] by thyroid hormone required a permissive dose of glucocorticoids (13). In addition to transcriptional regulatory mechanisms, thyroid hormone has also been shown to control gene expression by altering mRNA stability as documented for the TSH␤ subunit mRNA (14).
T HYROID hormone exerts prominent and characteristic effects on the cardiovascular system (1). Hyperthyroidism is associated with sinus tachycardia and atrial fibrillation, whereas the hypothyroid patient may experience bradycardia with prolonged QT intervals and polymorphic ventricular tachycardia or "torsade de pointes" (2, 3) . Thyroid hormones regulate the expression of specific cardiac genes (4, 5) and have also been shown to directly alter plasma membrane ion currents, including the outward K ϩ rectifying current (6) , the inward rectifier K ϩ current, I K1 (7) , and sodium currents (8, 9) . These effects may in turn alter action potential duration and susceptibility to ventricular arrhythmias. Regulation of the Kv1.5 gene has been shown in response to cardiac growth and development (10) , cAMP in cultured neonatal rat atrial myocytes (11) , and glucocorticoids in ventricular myocytes (12) . A recent study using adrenalectomized rats that were rendered hypothyroid suggested that induction of Kv1.5 gene transcription [as measured by messenger RNA (mRNA)] by thyroid hormone required a permissive dose of glucocorticoids (13) . In addition to transcriptional regulatory mechanisms, thyroid hormone has also been shown to control gene expression by altering mRNA stability as documented for the TSH␤ subunit mRNA (14) .
Recent studies have described very rapid effects of T 3 on the heart and systemic vasculature (15) . These observations suggest nongenomic actions of thyroid hormone (16) or the presence of T 3 -inducible proteins with a very short half-life. Since the half-life of Kv1.5 mRNA has been shown to be approximately 30 min (12) , a plausible hypothesis of a rapid response to thyroid hormone would encompass an effect on either Kv1.5 mRNA stability and/or gene transcription. In the present study, we examined the effect of experimental thyroid disease on Kv1.5 gene expression in the mammalian myocardium, both in the intact atria and ventricle as well as in cultured neonatal atrial and ventricular myocytes. The purpose of this work was to investigate possible molecular mechanisms that account for the effects of thyroid hormone on cardiac chronotropy (2) .
Materials and Methods Animals
Twenty-one Sprague Dawley (SD) rats, each weighing approximately 175 g, were divided into three groups. Group I remained untreated and served as the euthyroid control, group II received 6-n-propyl-2-thiouracil in the drinking water at a concentration of 750 mg/liter to induce the hypothyroid state, and group III received daily sc injections of l-thyroxine T 4 (20 g in 0.5 ml PBS) to induce the hyperthyroid state. Animals had access to rat chow and water ad libitum and were weighed every 4 days. After 12 days of treatment, heart rates were determined in lightly anesthetized animals (Brevitol, Eli Lilly, Indianapolis, IN) 40 mg/kg body wt) using echocardiogram standard limb leads I, II, and III placed at the limb extremities. Subsequently, the hearts were removed and the atria and left ventricles including the septum [left ventricle (LV)] were isolated and rapidly frozen in liquid nitrogen for RNA analysis.
In a second experiment, hypothyroid male SD rats were treated with T 3 (10 g/0.5 ml PBS), injected sc every 6 h for 24 h. Two rats were killed at each hour from 1 h to 5 h, four rats were killed at 6 h, and three rats were killed at 12 and 24 h after T 3 treatment was initiated. The LV and atria were rapidly removed and frozen for RNA analysis. Four rats of the same age served as euthyroid controls and four rats served as hypothyroid controls.
In a third series of experiments to measure Kv1.5 mRNA half-life, 12 euthyroid control and 12 hypothyroid male SD rats were injected with actinomycin D (1 mg/kg body wt, ip). Three animals were killed hourly between 0 -4 h after drug administration, and their hearts were removed for RNA analysis. In another protocol, a subgroup of hypothyroid and euthyroid rats were injected ip with T 3 (10 g/0.5 ml PBS) either at 1 h or 2 h after actinomycin D treatment. Three to four animals were killed at each 2-h and 4-h time point after T 3 administration for subsequent cardiac RNA extraction.
All chemicals used were of the highest purity available from Sigma Chemical Co. (St. Louis, MO).
RNA isolation
Total RNA was extracted from left ventricular and atrial tissues by the acid-phenol method as previously described (4) . The RNA was quantified by OD at 260 nm, and its integrity was verified by ethidium bromide intercalation of the 28S and 18S ribosomal RNA resolved by gel electrophoresis. Northern blot analysis of the myosin heavy chain (MHC) mRNAs used 5 g of total RNA isolated from LVs as previously described (17) . ␣-Tubulin, ␣-MHC, and ␤-MHC mRNAs were detected by hybridization to unique 40-base oligonucleotide probes (Oncogene Science, Inc., Uniondale, NY). Probe hybridization and wash conditions were as previously reported (17) .
Cultured neonatal rat cardiac myocytes
Ventricular and atrial myocytes were prepared as previously described (4). Briefly, hearts were removed from 2-day-old neonatal rats and trimmed free of the major vessels; under a magnifying scope the atria and ventricles (left and right chambers not separated) were separated by cutting along the atrioventricular groove. Tissues were minced and incubated in collagenase-containing medium, and the released cells were collected by centrifugation. After four rounds of enzymatic digestion, the cells were preplated in noncoated T75 culture flasks for 20 min. Nonadherent cells were then removed, resuspended in PC-1 medium (Hycor Biomedical, Portland, ME), and plated onto collagen-coated plates at a density of approximately 1.5 ϫ 10 Ϫ6 /962 mm 2 and were allowed to adhere for 18 h. The myocytes were subsequently maintained in DMEM/F12 medium (Gibco BRL, Gaithersburg, MD) supplemented with insulin (120 IU/liter), transferrin (5 mg/liter), selenium (5 g/ liter), dexamethasone (10 Ϫ7 m), with or without T 3 (10 Ϫ8 m) for 48 h when cells were harvested for RNA analysis. Reagents were tissue culture grade from Sigma Chemical Co. The media were changed daily.
Quantitative RT-PCR analysis
A competitive quantitative RT-PCR (QRT-PCR) method was developed to determine the copy number of Kv1.5 mRNA per g of total RNA from cardiac tissue and in cultured cardiomyocytes (18) . This competitive PCR method used an homologous internal standard that amplified with similar kinetics to the endogenous rat Kv1.5 cDNA since both DNA sequences were identical except the standard was shorter by 215 bp. The internal standard (189 bp) was developed by deletion of 215 bp of the Kv1.5 cDNA sequence from nucleotide position 2171 to 2574 (GenBank M27158).
The following primers were used for the amplification reaction: (upstream primer, 5Ј-GGCTATGGAGACATGAGACCCATC-3Ј and downstream primer, 5Ј-TCTCTTTACAAATCTGTTTCACGG-3Ј). In the RT reaction, 5 or 10 g of total RNA were combined with 25 pmol of downstream PCR primer, and first-strand cDNA was synthesized using 200 U MMLV reverse transcriptase (RTase) (Stratagene, La Jolla, CA) in a reaction mixture containing 40 U of RNAsin, 50 mm Tris-HCl (pH 8.3), 75 mm KCl, 10 mm dithiothreitol, 3 mm MgCl 2 , and 1 mm deoxynucleoside triphosphates (dNTPs). After incubation for 1 h at 37 C, the RTase was inactivated by heating the reaction mixture to 94 C for 6 min. Three microliters of the RT reaction were used for each amplification reaction in a final volume of 50 l containing 2.5 U AmpliTaq Gold DNA polymerase (Perkin-Elmer Corp., Norwalk, CT), 50 mm KCl, 10 mm Tris-HCl, pH 8. , or 1.23 ϫ 10 Ϫ21 mol) was amplified as follows: 45 sec denaturation at 94 C, 45 sec annealing at 55 C, 1 min extension at 72 C, for 30 cycles. PCR products (20 l) were resolved by electrophoresis on 2% agarose gels and quantified by ethidium bromide intercalation. The intensity of UV fluorescence was quantified using a Molecular Imager system (Bio-Rad Laboratories, Inc., Hercules, CA).
Data analysis
Absolute amounts of Kv1.5 mRNA in moles per g total RNA were estimated by this equation: [mol wt factor ϫ moles standard cDNA at the equivalence point ϫ dilution factor for the amount of RNA used in the PCR]. The mol wt factor corrects for the difference in mol wt between the endogenous and standard PCR products. The equivalence point was reached when the competitor and sample DNA fragments yielded equally intense ethidium bromide-stained bands. The log of the ratios of sample to competitor PCR products was graphed as a function of the log of the initial amount of standard added to each PCR reaction. The molar amount of Kv1.5 mRNA was determined by linear regression analysis of these data. All results were expressed as means Ϯ sem. The unpaired t test was used for statistical comparison of two groups.
The half-life of Kv1.5 mRNA was determined by calculating from the equation: t 1/2 ϭ ln2/k, where t 1/2 is the half-life, and k is the first-order degradation rate constant (19) . The number of moles Kv1.5 mRNA in each RNA sample was converted into a natural logarithm for use in this equation.
Results

Thyroid status of animals
The thyroid status of the experimental animal groups was assessed by measurements of heart rate, heart size, and the thyroid hormone-responsive MHC genes (20) . The well known effects of thyroid hormone on cardiac mass are supported by the LV weights and the LV to body weight (LV/ BW) ratios (20, 21) . LV weights (mg) for the euthyroid, hyper-, and hypothyroid rats were 639 Ϯ 7, 777 Ϯ 19, and 435 Ϯ 12, respectively, and LV/BW ratios (mg/g) of 2.26 Ϯ 0.03, 2.74 Ϯ 0.05, and 2.08 Ϯ 0.04; both measures were significantly different among all the groups (P Ͻ 0.05; n ϭ 7 per group). The mean heart rate of the hypothyroid animals was 305 Ϯ 8 beats/min, which was significantly lower (P Ͻ 0.001) than the euthyroid controls at 431 Ϯ 18 beats/min. T 3 treatment of hypothyroid animals for 24 h significantly increased the heart rate to 370 Ϯ 8 beats/min (P Ͻ 0.05).
Expression of ␣-and ␤-MHC genes in rat ventricles was measured by Northern blot analysis as previously published (21) . The ␤-MHC isoform mRNA was expressed only in the hypothyroid state, whereas ␣-MHC was the exclusive MHC isoform expressed in euthyroid controls and in the hyperthyroid animals that were treated daily with thyroid hormone (ϩT 4 ). Figure 1 shows a representative Northern blot of ␤-MHC and ␣-tubulin mRNA in animals from the three treatment groups. These data confirm the validity of the experimental model for hypo-and hyperthyroidism, as we have previously reported (4, 20, 21) .
Quantitation of Kv1.5 mRNA by RT-PCR analysis
Since expression of Kv1.5 is very low in the rat heart, we developed a method for quantitation of Kv1.5 mRNA levels based on a competitive RT-PCR method using an homologous Kv1.5 DNA standard. To optimize the QRT-PCR so that the quantity of the amplified product would be directly proportional to the quantity of the starting target sequence, a range of concentrations of sample RNA and of standard DNA and the number of amplification cycles were varied (18) . As shown in Figure 2a , the moles of homologous Kv1.5 DNA standard that were added to each competitive PCR reaction fell within the exponential phase of the reaction after 30 cycles. Similarly, when total cardiac RNA was varied from 75-600 ng in the PCR reaction, the amount of amplified product was within the exponential phase of the reaction after 30 cycles as shown in Figure 2b . From these data, we selected a PCR protocol of 30 cycles using an average of 300 ng total RNA and 10 Ϫ19 to 1.23 ϫ 10 Ϫ21 mol of standard. Figure 3a shows the competitive QRT-PCR analysis from euthyroid (panel A) and hypothyroid (panel B) ventricular RNA samples, illustrating the ethidium bromide-stained amplified DNA from a series of five competitive reactions. The slower migrating 404-bp fragment in each reaction is the amplified product of endogenous Kv1.5 cDNA, while the 189-bp fragment is the internal standard added at 3-fold decreasing amounts to each of five reactions (shown left to right). These data are plotted in Fig. 3b with each datum point derived from the densitometric measurement of the standard and endogenous Kv1.5 products from each RT-PCR reaction. Linear regression analysis was used to calculate the absolute molar amount of steady-state Kv1.5 mRNA in hypothyroid and euthyroid ventricles by determining the molar equivalence point between standard and endogenous PCR products (Fig. 3b) . The correlation coefficient of the linear regression curves for all data used in these studies was greater than 0.985.
To rule out possible contamination by genomic DNA, we performed the RT-PCR reactions containing all PCR reagents and RNA templates without reverse transcriptase. In addition, Southern blotting of the PCR reaction products and hybridization with an oligonucleotide probe complementary to the Kv1.5 sequence immediately 5Ј of the downstream PCR primer, as well as direct sequencing of this fragment, confirmed that the 404-bp PCR product was rat Kv1. 5.
Cardiac Kv1.5 mRNA expression in thyroid disease states
Kv1.5 mRNA content in the euthyroid LV was 4.25 Ϯ 0.60 ϫ 10 Ϫ20 mol/g RNA. These levels were significantly (P Ͻ 0.01) decreased by 70% to 1.27 Ϯ 0.80 ϫ 10 Ϫ20 mol/g total RNA in 6-n-propyl-2-thiouracil-treated hypothyroid animals (Fig. 4) . Treatment of euthyroid animals with T 4 to render them hyperthyroid did not alter LV expression of Kv1.5 mRNA (4.36 Ϯ 0.53 ϫ 10 Ϫ20 mol/g RNA) compared with euthyroid (Fig. 4) . Measurements of Kv1.5 mRNA in atria from euthyroid animals were higher than in the LV at 6.10 Ϯ 0.37 ϫ 10 Ϫ20 mol/g RNA. In contrast to ventricular myocardium, Kv1.5 mRNA content in the atria showed no dependence on thyroid status. Atrial Kv1.5 transcript levels in hypothyroid animals were 6.67 Ϯ 0.88 ϫ 10 Ϫ20 mol/g RNA, which did not differ significantly from euthyroid con- 
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CARDIAC Kv1.5 CHANNEL EXPRESSION trols (Fig. 4) . Furthermore, administration of T 4 to euthyroid animals to render them hyperthyroid did not alter expression of Kv1.5 in the atria (5.55 Ϯ 0.50 ϫ 10 Ϫ20 mol/g RNA).
Time course of T 3 effects on cardiac gene expression
To determine the time course of the response of Kv1.5 expression to thyroid hormone, T 3 was administered to hypothyroid rats every 6 h over a 24-h period. Kv1.5 mRNA expression in hypothyroid LV tissue was restored to euthyroid levels within 1 h after T 3 treatment and remained at euthyroid levels over the 24-h period (Fig. 5) . Simultaneous analysis of atrial tissue of these rats showed that hypothyroidism did not alter steady-state levels of Kv1.5 mRNA (Fig.  4) , and that T 3 treatment of the hypothyroid atrium had no effect over this time course (data not shown).
We compared the time course of the thyroid response of the Kv1.5 gene to that of the well known cardiac thyroid hormone-responsive ␣-and ␤-MHC genes. Northern blot analysis was used to measure steady-state levels of ␣-and ␤-MHC mRNAs in ventricles of hypothyroid rats treated with T 3 for 6, 12, and 24 h. In the hypothyroid ventricle (n ϭ 12), only the ␤-MHC mRNA isoform was expressed (Fig. 1) , which remained unaltered at 6 h and 12 h of T 3 treatment, but by 24 h the steady-state levels had decreased by 51 Ϯ 1%, similar to that previously reported by our laboratory (22) . This decrease of ␤-MHC mRNA in response to T 3 treatment indicates an apparent half-life of approximately 24 h. In contrast, the appearance of ␣-MHC mRNA was 25 Ϯ 3% of euthyroid values at 12 h of T 3 treatment and 170 Ϯ 3% of euthyroid values at 24 h, indicating a more rapid on-rate of appearance of this transcript with a half-life of less than 24 h.
Effect of T 3 on Kv1.5 mRNA half-life
To determine whether the rapid increase of ventricular Kv1.5 mRNA in response to thyroid hormone was the result of an increase in transcription or a change in mRNA half-life, we measured Kv1.5 mRNA disappearance over a 4-h period in both euthyroid and hypothyroid rats treated with actinomycin D, an inhibitor of transcription. Figure 6 shows ventricular Kv1.5 mRNA values derived by QRT-PCR (average values of 3 rats per time point) after actinomycin D treatment. The calculated mRNA half-life in the euthyroid ventricles was 1.9 h, which was not significantly different from the 2.0-h half-life in the hypothyroid ventricles. Furthermore, in another series of experiments in which euthyroid and hypothyroid rats were treated with T 3 after transcription was inhibited by actinomycin D, the half-life of Kv1.5 mRNA was not altered, suggesting that the rapid increase in Kv1.5 mRNA in response to T 3 in the hypothyroid heart is unlikely to be mediated by a significant increase in mRNA stability.
Kv1.5 expression in cultured neonatal cardiac myocytes
To determine that the Kv1.5 mRNA measured in intact ventricular myocardium was representative of that derived from the cardiac myocyte rather than nonmuscle cells, we studied purified cultures of neonatal myocytes. The molar amount of Kv1.5 mRNA in cultured neonatal rat atrial myocytes (7.5 Ϯ 1.7 ϫ 10 Ϫ20 mol/g RNA) was similar to that measured in the intact 2-day-old rat atria (4.8 Ϯ 0.4 ϫ 10 Ϫ20 mol/g RNA) and in the adult atria (6.1 Ϯ 0.4 ϫ 10 Ϫ20 mol/g RNA). In contrast, cultured ventricular neonatal myocyte Kv1.5 mRNA levels (0.6 Ϯ 0.04 ϫ 10 Ϫ20 mol/g RNA) were lower than the intact neonatal ventricle (4.4 Ϯ 0.9 ϫ 10 Ϫ20 mol/g RNA) and the adult ventricles (4.3 Ϯ 0.6 ϫ 10 Ϫ20 ). The response of Kv1.5 to thyroid hormone in cultured myocytes was similar to that observed in the intact heart. In the absence of T 3 in the culture medium, Kv1.5 mRNA decreased significantly in the ventricular myocytes, whereas no effect on expression was observed in cultured atrial myocytes.
Discussion
Many of the cellular actions of thyroid hormone are mediated by binding to nuclear receptors that regulate the transcription rate of specific genes (23) . In the heart, numerous genes encoding structural and regulatory proteins are thyroid hormone responsive, and changes in their expression explain in part the cardiac manifestations of thyroid disease, including myocardial contractility and chronotropy. In addition to well known T 3 -responsive cardiac genes, including ␣-and ␤-MHC, sarcoplasmic reticulum Ca 2ϩ -activated ATPase (SERCA2), ␤-adrenergic receptors, T 3 nuclear receptors, and Na/K-ATPase, a recent report suggests that Kv1.5 was induced by chronic thyroid hormone and dexamethasone treatment of the hypothyroid-adrenalectomized rat (13) . Earlier reports have also identified changes in the expression of other K ϩ -channel genes, including Kv1.4, 4.2, and 4.3, in response to T 3 treatment (24) .
In the present study we observed that the significantly lower content of Kv1.5 mRNA in the hypothyroid ventricle was increased 4-fold to euthyroid levels within 1 h of T 3 treatment. This response was more rapid than the induction of the cardiac-specific ␣-MHC gene, which required between 12 h and 24 h of thyroid hormone treatment to reach euthyroid levels. Several molecular mechanisms by which thyroid hormone regulates Kv1.5 expression can be postulated. If transcription of the Kv1.5 gene is induced, then this represents the most rapid nuclear effect of T 3 reported to date (23) . This result is somewhat surprising in view of the lack of a canonical thyroid response element within the Kv1.5 promoter (11) . Alternatively, T 3 may be acting to preserve the stability of the Kv1.5 transcript, similar to that shown for TSH-␤ mRNA (14) and for the ␣-MHC gene in the heart (25) . Using actinomycin D to inhibit transcription, we determined that the half-life of ventricular Kv1.5 mRNA was not statistically different between euthyroid and hypothyroid rats. When either euthyroid or hypothyroid rats were treated with T 3 , the half-life was not prolonged as would be expected if mRNA stability was the primary mechanism by which T 3 rapidly increased Kv1.5 mRNA. However, due to the short 
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CARDIAC Kv1.5 CHANNEL EXPRESSION half-life and the small cellular pool of Kv1.5 mRNA, experiments to inhibit transcription with actinomycin D while simultaneously treating hypothyroid animals with T 3 present a complex kinetic model. It is also important to recognize that the apparent on-rate or induction of transcription may differ from the off-rate of this reaction so that measuring the rate of decrease in Kv1.5 mRNA after actinomycin D treatment is likely to be different from its more rapid increase in the hypothyroid animal treated with T 3 . Since the present study measures cellular mRNA content, which depends not only on the rate of transcription, RNA processing, and nuclear export, but also on mRNA degradation, the effects seen by T 3 may well involve multiple sites of regulation.
We have reported that expression of T 3 receptors in the hypothyroid myocardium differs from that in the euthyroid heart, providing an explanation for the apparent increased sensitivity of the hypothyroid myocardium to T 3 (22) . In the hypothyroid heart, the response of several T 3 -responsive genes, including SERCA2 and ␣-MHC, to T 3 treatment results in an increase in expression that is higher than euthyroid control levels, suggesting enhanced sensitivity (20, 22, 26) . Therefore, we postulate that T 3 treatment of the hypothyroid and the euthyroid heart are not comparable, and this may explain in part the lack of effect of T 3 on Kv1.5 mRNA levels in the euthyroid ventricle, whereas the hypothyroid ventricle responds rapidly. Alternatively, the serum levels of T 3 in euthyroid animals may be sufficient to maximally stimulate Kv1.5 gene expression. Previous studies have reported the level of expression of various voltage-gated K ϩ channels in the rat heart (27) . Those studies and the present data show that expression of Kv1.5 mRNA is approximately 30% higher in atrial compared with ventricular myocardium. These data are in contrast to studies of Kv1.5 mRNA using an RNA protection assay in which expression was shown to be more abundant in ventricles than in atria, and only ventricular expression was induced by glucocorticoids (28) . Since the intact ventricle and atrium consist of multiple cell types, we compared the expression of Kv1.5 mRNA in purified cultures of atrial and ventricular myocytes. Not only was Kv1.5 mRNA present in the purified myocytes, its expression was modified by T 3 similar to that observed in vivo. As has been reported for the cardiac-specific ␣-MHC gene (29) , expression of Kv1.5 in atrial tissue was unresponsive to thyroid hormone. These data are also consistent with the observation that atrial arrhythmias are a rare occurrence in the hypothyroid patient (2) .
Hypothyroidism is characterized by bradycardia and a long QT interval (2) . Although this prolongation of the action potential may be the result of changes in a number of ion currents, including repolarizing K ϩ currents (30), the role of Kv1.5 in the repolarizing phase of the action potential within the mammalian ventricle is unclear. The ultrarapid delayed rectifier K ϩ current (I kur ) has been reported to be carried by the Kv1.5 channel (31). The Kv1.5 protein has been immunolocalized to human atrial and ventricular myocytes (31, 32) and, when studied in patients with atrial fibrillation, was shown to be altered, contrary to what would have been predicted based upon its proposed function (33) . Western analysis of Kv1.5 protein in rat ventricles in the present study showed that the protein content decreased 20 -60% in the hypothyroid hearts compared with euthyroid (data not shown). Whether regulation of Kv1.5 expression by thyroid hormone is similar in rat and human remains to be determined. However, if the marked decrease in the ventricular Kv1.5 gene product results in a decrease of the delayed rectifier K ϩ current, then this may in part contribute to the prolongation of the QT interval observed in hypothyroidism (2) . Similarly, if the rapid response of Kv1.5 to thyroid hormone observed in the present experimental study occurs in humans, then this may have implications in the treatment of patients with varying degrees of hypothyroidism, as well as the potential utility of T 3 therapy in cardiac surgery patients in which serum T 3 levels are significantly reduced (15) .
